Navigation Links
Helix BioPharma Chairman resigns
Date:10/15/2007

AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864) announced today that Jerome F. McElroy has resigned as Chairman and a director of the Company to pursue his retirement interests.

"Jerry has had a long involvement with the Company since its amalgamation in 1995," said Don Segal, President and Chief Executive Officer. "On behalf of the Company, I thank him for his positive contributions and wish him well with his future endeavors."

The Company has entered into an agreement with Mr. McElroy in respect of his resignation, pursuant to which Mr. McElroy will receive the equivalent of approximately one year's salary and benefits in a lump sum payment made today of $350,000, plus termination payments for one year of $3,000 per month and contributions to his medical benefits of $12,000 per year for four years.

The Company will designate a new Chairman to succeed Mr. McElroy in the near term.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker symbol "HBP".

This News Release contains certain forward-looking statements and information regarding Helix's product development initiatives, Topical Interferon Alpha-2b and L-DOS47. Forward-looking statements and information can be identified by the use of forward-looking terminology such as "developing" and "initiatives". Helix's actual results could differ materially from those anticipated in these forward-looking statements and info
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kyron appoints former AMA chairman to board
2. Third Wave appoints new chairman
3. Cisco Chairman donates $31 million for UW building renovation
4. Bone Care Names New Chairman
5. Cisco Chairman Praises University Research
6. JT Packard exec resigns after settling copyright disputes
7. Donley resigns as WiCell director
8. Renaissance Learning CEO resigns to start company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY ... The Boston Area Chapter of ISPE (International Society for ... for Wed., Oct. 1 at Gillette Stadium Clubhouse in ... in ISPE Boston’s long history, with more than 375 ... , HOLLOWAY AMERICA President David Simpson is looking ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Smilodon ranks alongside Tyrannosaurus rex as the ultimate killing ... was a fearsome predator of Ice-Age America,s lost giants. ... debated how this iconic predator used its ferocious fangs ... published today in the US Proceedings of the National ...
... 1 Boston Scientific,Corporation (NYSE: BSX ) will ... quarter ended September 30, 2007 on Friday,October 19, at ... by Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, ... Chief Financial Officer. The live webcast and archived ...
... Space Center,has awarded a five-year, $120-million extension of ... Institute, also known,as NSBRI, of Houston. Under the ... continue biomedical research in support of a,long-term human ... the cooperative agreement began April 1, 1997, with,a ...
Cached Biology Technology:Scientists say sabercat bit like a pussycat 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... Calif. Beyond the personal tragedy of chronic alcoholism ... know severe alcoholism stresses the heart and that mitochondria, ... But they don,t know the precise mechanism. Now ... Center of the New York State Department of Health ...
... 22, 2012 -- The first clinical trial of a ... by the Infectious Disease Research Institute (IDRI), a Seattle-based ... diseases of poverty. The Phase 1 trial is taking ... trial planned in India, an epicenter of the disease. ...
... an outbreak of airborne H5N1 influenza in humans needs to ... can safely continue H5N1 research and share the results among ... mBio , the online open-access journal of the American Society ... been at the center of heated discussions in science and ...
Cached Biology News:A change of heart 2First vaccine against fatal visceral leishmaniasis enters clinical trial 2First vaccine against fatal visceral leishmaniasis enters clinical trial 3Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: